The FDA granted accelerated approval to Novo Nordisk’s Wegovy for adults with metabolic dysfunction-associated steatohepatitis (MASH) featuring moderate-to-advanced liver fibrosis. This marks Wegovy as the first GLP-1 receptor agonist cleared for this prevalent liver condition affecting an estimated 22 million Americans. Approval was based on Phase 3 data showing improvement in liver scarring and MASH resolution. The move positions Wegovy in competition with Madrigal Pharmaceuticals’ Rezdiffra, another FDA-approved MASH treatment with strong sales momentum.